MV Electrosystems IPO: Date, Price, GMP, Allotment & Review.

MV Electrosystems IPO: Q-Line Biotech Ltd. (QBL) is coming up with its maiden IPO through the book-building route, offering investors an opportunity to participate in a company operating in the in-vitro diagnostics (IVD), diagnostic reagents, consumables and equipment segment.

The company has announced an IPO price band of ₹326 to ₹343 per share. The issue will open for subscription on May 21, 2026, and close on May 25, 2026. The shares are proposed to be listed on NSE SME Emerge.

While Q-Line Biotech has demonstrated strong revenue growth, investors should also examine its declining FY25 profit, higher borrowings, contingent liabilities and the sustainability of its strong 9M FY26 earnings before making an investment decision.

🔎 Q-Line Biotech IPO – Key Details

🏢 Q-Line Biotech IPO: About the Company

Q-Line Biotech Ltd. is engaged in the development, manufacturing and marketing of diagnostic reagents, kits, point-of-care (POC) devices and consumables.

The company also manufactures, imports, distributes and supplies diagnostic equipment for a variety of healthcare and diagnostic requirements.

Since 2013, Q-Line Biotech has supplied diagnostic equipment and IVD products directly or through distributors, primarily to:

• Diagnostic service providers
• Hospitals
• Medical colleges
• Healthcare institutions

Over the years, the company says it has established its brands through its experience, research and development capabilities, manufacturing infrastructure and quality-assurance processes.

Its major operating segments include:

• 🧪 Clinical Chemistry
• 🩸 Haematology
• 🔬 Immunodiagnostics
• 🧬 Molecular Diagnostics
• 🩺 Point-of-Care Devices
• ⚡ Rapid Diagnostic Products

🧬 Q-Line Biotech’s Manufacturing & R&D Capabilities

Q-Line Biotech’s manufacturing activities include indigenous production of reagents used in clinical chemistry, haematology, immunodiagnostics and molecular diagnostics.

The company also manufactures and supplies IVD, pathology equipment and diagnostic devices.

During the COVID-19 pandemic, Q-Line Biotech expanded into COVID-related testing products through technical collaborations with third-party institutions and its own R&D team.

Its COVID-related portfolio included:

• RT-PCR kits
• RNA extraction kits
• VTM kits

The company also has technical collaborations with international companies for certain classes of reagents, equipment and devices. Under these arrangements, Q-Line Biotech manufactures products according to the technical specifications provided by its partners.

According to the information provided in the offer document, these collaborations are intended to help the company’s products meet applicable quality-control requirements, international standards and certifications.

As of March 31, 2026, Q-Line Biotech had 19 employees working in its R&D laboratories, representing 5.25% of its total permanent workforce.

The company had 362 employees on its payroll, along with 223 contract employees, as of the same date.

💰 Q-Line Biotech IPO Issue Details

Q-Line Biotech is launching its maiden IPO through the book-building process.

The company is offering 62,53,200 equity shares having a face value of ₹10 each. At the upper end of the price band, the issue is expected to mobilize approximately ₹214.48 crore.

The IPO price band has been fixed at:

₹326 – ₹343 per share

The minimum application size is 800 shares, with additional applications allowed in multiples of 400 shares.

At the upper price band of ₹343, one minimum lot would require an investment of:

800 × ₹343 = ₹2,74,400

The issue represents approximately 26.81% of the company’s post-IPO paid-up capital.

📌 How Q-Line Biotech Plans to Use IPO Funds

The company plans to use the IPO proceeds for:

• ₹93.50 crore – Working capital requirements
• ₹90.00 crore – Repayment/prepayment of certain borrowings
• Balance amount – General corporate purposes

The proposed use of funds indicates that a substantial portion of the IPO proceeds will be directed toward strengthening working capital and reducing debt-related obligations.

💵 Q-Line Biotech Pre-IPO Placement

Before the IPO, Q-Line Biotech raised ₹27.44 crore through a pre-IPO placement.

The company issued 8,00,000 shares at ₹343 per share in May 2026.

This is the same as the upper end of the IPO price band.

📊 Q-Line Biotech IPO Market Capitalisation

Following the IPO, the company’s paid-up equity capital is expected to increase from approximately ₹17.07 crore to ₹23.33 crore.

At the upper IPO price of ₹343 per share, Q-Line Biotech is looking at an estimated market capitalisation of approximately:

₹800.16 crore

🏦 Q-Line Biotech IPO Lead Managers & Registrar

The IPO is jointly managed by:

• Hem Securities Ltd.
• Share India Capital Services Pvt. Ltd.

Registrar: Purva Sharegistry (India) Pvt. Ltd.

Market Maker/Syndicate Member: Hem Finlease Pvt. Ltd.

📈 Q-Line Biotech Capital History

Q-Line Biotech initially issued equity shares at par value and subsequently raised equity capital at prices ranging from ₹125 to ₹417 per share between March 2019 and May 2026.

The company has also issued bonus shares on two occasions:

• 2:1 bonus issue in March 2016
• 9:1 bonus issue in August 2025

The average acquisition cost of shares for certain promoter holdings is stated as ₹0.00, ₹0.04 and ₹18.34 per share, as disclosed in the offer document.

📊 Q-Line Biotech Financial Performance

Q-Line Biotech’s financial performance shows a significant increase in revenue over the reported periods. However, profitability has been more inconsistent.

📌 FY2023

The company reported total income of ₹184.81 crore and net profit of ₹32.10 crore.

📌 FY2024

Total income increased to ₹206.45 crore, while net profit rose to ₹34.44 crore.

⚠️ FY2025

Revenue increased sharply to ₹322.58 crore, but net profit declined to ₹28.13 crore.

The decline in profit despite strong revenue growth is an important factor investors should consider.

The company reported an extraordinary item of approximately ₹16.97 crore, which affected its FY25 profitability.

🚀 9M FY2026

For the nine months ended December 31, 2025, Q-Line Biotech reported total income of ₹236.50 crore and net profit of ₹38.69 crore.

The strong nine-month profit is notable because it already exceeds the full-year FY25 PAT of ₹28.13 crore.

However, investors should assess whether this level of profitability can be sustained after listing rather than assuming that the 9M FY26 performance will automatically continue.

📉 Q-Line Biotech Profitability & Valuation

For the last two reported fiscal years, the company reported an average EPS of approximately ₹25.00 and an average Return on Net Worth (RoNW) of 23.17%.

Based on the NAV of ₹140.81 per share as of December 31, 2025, the IPO is priced at approximately 2.44 times price-to-book value (P/BV).

The offer-document information provided does not include post-IPO NAV data.

Based on the information provided:

• P/E based on FY26 earnings: approximately 15.51x
• P/E based on FY25 earnings: approximately 28.44x

The difference is significant because FY26 profitability has increased sharply compared with FY25.

💡 What Does the Valuation Mean?

The IPO valuation looks more reasonable if investors assume that the company’s stronger 9M FY26 profitability is sustainable.

However, if FY25’s lower profitability is a better indicator of normalized earnings, the valuation appears considerably more demanding.

Therefore, earnings sustainability is one of the most important factors to monitor in the Q-Line Biotech IPO.

📌 PAT Margin & RoCE

Q-Line Biotech reported the following PAT margins:

• FY23: 17.56%
• FY24: 16.92%
• FY25: 8.97%
• 9M FY26: 16.65%

RoCE stood at:

• FY23: 22.14%
• FY24: 19.25%
• FY25: 17.66%
• 9M FY26: 13.32%

The sharp decline in PAT margin during FY25 followed by a recovery in 9M FY26 highlights the volatility in the company’s profitability.

⚠️ Q-Line Biotech IPO: Key Risks

Investors should not look only at the company’s revenue growth and recent profit improvement. Several risks deserve attention.

1. Profitability declined in FY25

Although revenue increased substantially in FY25, net profit fell to ₹28.13 crore from ₹34.44 crore in FY24.

2. Sustainability of 9M FY26 earnings

The company generated ₹38.69 crore PAT during 9M FY26. This is a strong improvement, but investors should consider whether this performance can be maintained over the full year and beyond.

3. High borrowings

The company’s total borrowings stood at approximately ₹242.57 crore as of December 31, 2025.

Debt levels are therefore an important consideration, particularly when assessing the company’s balance-sheet strength.

4. Contingent liabilities

Contingent liabilities stood at approximately ₹61.64 crore as of December 31, 2025.

Investors should carefully review the nature and potential financial impact of these liabilities in the offer document.

5. No directly comparable listed peer

According to the offer-document information provided, Q-Line Biotech does not have a directly comparable listed peer.

This makes valuation comparison more difficult for investors.

6. SME IPO considerations

Since the proposed listing is on NSE SME Emerge, investors should also consider the characteristics and risks associated with SME-listed companies, including liquidity and market volatility.

💸 Q-Line Biotech Dividend History

Q-Line Biotech has not paid dividends during the reported periods covered by the offer document.

The company intends to follow a prudent dividend policy based on its financial performance, future prospects and other relevant considerations.

Investors looking primarily for dividend income may therefore find the IPO less attractive.

🏭 Q-Line Biotech IPO Peer Comparison

The offer document states that Q-Line Biotech has no listed peers for direct comparison.

The provided peer table includes companies such as Powerica, Cummins India, Kirloskar Oil Engines, NTPC Green Energy, ACME Solar Holdings and Adani Green Energy. However, these companies operate in different industries and therefore should not be treated as direct business comparables for Q-Line Biotech.

Note: The above companies are not direct business peers of Q-Line Biotech. The figures are based on the information provided and are intended only as the disclosed comparison data.

🏦 Merchant Bankers’ Track Record

According to the information provided, the two merchant bankers associated with the issue have handled 79 issues over the past three years.

Of these, 8 issues closed below their issue price on the listing date.

Past issue performance, however, should not be considered a guarantee of the future performance of Q-Line Biotech shares.

🔍 Q-Line Biotech IPO Review: Positive Factors

There are several factors that may attract investors:

✅ Presence in the growing diagnostics and IVD industry

✅ In-house R&D and manufacturing capabilities

✅ Diversified product portfolio across diagnostic segments

✅ Technical collaborations with international companies

✅ Strong revenue growth in FY25

✅ Significant improvement in 9M FY26 profitability

✅ Part of the IPO proceeds will be used to reduce borrowings

⚠️ Q-Line Biotech IPO Review: Negative Factors

At the same time, investors should consider:

❌ FY25 net profit declined despite strong revenue growth

❌ Profitability has shown volatility

❌ High borrowings of around ₹242.57 crore

❌ Contingent liabilities of around ₹61.64 crore

❌ Sustainability of 9M FY26 earnings needs to be assessed

❌ No directly comparable listed peer

❌ IPO valuation may appear demanding if FY26 earnings normalize

❌ SME listing can involve higher liquidity and volatility risks

📝 Q-Line Biotech IPO Review: Should You Apply?

Q-Line Biotech operates in the diagnostics and IVD industry and has built capabilities across reagents, consumables, diagnostic equipment and POC products.

The company’s revenue growth is encouraging, while its 9M FY26 profit performance is particularly strong. Its R&D capabilities, manufacturing operations and technical collaborations are additional positives.

However, investors should also look beyond the headline revenue growth.

The decline in FY25 net profit, substantial borrowings, contingent liabilities and uncertainty over the sustainability of the sharp 9M FY26 profit improvement are important concerns.

The IPO also does not have a directly comparable listed peer, making valuation assessment more difficult.

🎯 Our View

Q-Line Biotech IPO appears suitable for investors who understand the risks associated with SME IPOs and are willing to take a medium- to long-term view.

At the upper price band, the valuation does not appear particularly cheap when FY25 earnings are considered. The valuation becomes more comfortable only if the company’s improved 9M FY26 profitability proves sustainable.

Risk-conscious investors may prefer to wait for greater clarity on earnings and debt reduction, while well-informed investors with a higher risk appetite may consider a moderate allocation for the long term.

Investors should carefully read the Red Herring Prospectus/offer document, evaluate the company’s financial statements and understand SME-market risks before applying.

📌 Q-Line Biotech IPO – Final Verdict

Q-Line Biotech has a promising presence in the diagnostics and IVD sector, but the IPO comes with both opportunities and meaningful risks.

The strongest positives are its diversified product portfolio, manufacturing and R&D capabilities, revenue growth and strong 9M FY26 profit.

On the other hand, FY25 profit weakness, debt, contingent liabilities and the sustainability of recent earnings remain key concerns.

👉 Overall view: Apply only if you are comfortable with the risks and have a medium- to long-term investment horizon.

⚠️ Disclaimer

This article is for informational and educational purposes only and should not be considered investment advice. IPO investments involve market, liquidity, valuation and business risks. Investors should independently evaluate the offer document, financial statements, risk factors and their own investment objectives before making any investment decision.